Compare Globalstar (GSAT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globalstar vs Tango Therapeutics Inc. — how do they compare? Globalstar trades at $81.7 (market cap $10.71B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Globalstar is far larger — about 2.9× Tango Therapeutics Inc.'s market cap, and Globalstar is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 23 Days and Tango Therapeutics Inc. for 0 Days on average.
| GSAT | TNGX | |
|---|---|---|
Market Cap | $10.71B | $3.75B |
Volume | 768,707 | 9,619,106 |
Sector | Media | Health |
52-Week High | $84.43 | $32.90 |
52-Week Low | $41.54 | $7.50 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $10.71B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.
Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Globalstar
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
